The Kuhn group recruited patients with mild and moderate cognitive deficits for their pilot study [15] with a flyer, in which they stated: “It cannot even be excluded that DBS effects a slow-down of disease progression, e.g. through the release of neurotrophins. The gene discussed is BDNF; the disease is Cognitive impairment.